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Hepatitis A Vaccine
Hepatitis A is a significant infectious disease that occurs worldwide. The ease of
travel has facilitated the transmission of this disease, thereby increasing the number
of individuals at risk. Most hepatitis A infections resolve without serious sequelae,
and a good number of infected individuals are asymptomatic. Although most
symptomatic infections are self limiting and are not responsible for any significant
morbidity or mortality, this infection does result in a considerable economic
burden, with an estimated cost of $200 million annually.
The most logical approach to the management of this disease is prevention
because no treatment currently exists. The transmission of this virus occurs essen-
tially by the fecal-oral route. Therefore, prevention has focused on avoiding
exposure and promoting hygienic measures. An important preventive measure as
well as partial treatment is the use of human immune globulin, which contains
antibodies against the hepatitis A virus.
The successful development of a vaccine could lead to the eradication of the
hepatitis A virus because the human is the only natural reservoir. This vaccine is
prepared by treating the virus with formaldehyde, which produces an inactivated
virus without destroying its antigenic character, thereby allowing the recipient of
the vaccine to manifest an antibody response. In several studies, the vaccine has
proven to be safe, well tolerated, and immunogenic in all groups tested. When the
vaccine has been administered to adults, the vaccine-induced antibodies have been
present for over one year. When a booster dose has been administered 6-12 months
after the initial vaccination, extremely high antibody titers have been produced.
Moreover, it has been mathematically determined that the administration of a
booster vaccination has the potential of producing protective antibodies for more
than 20 years.
Discussions will likely continue regarding which groups should receive the
vaccine. The first group recommended to receive the inactivated hepatitis A
vaccine includes children. Other groups that have been designated to receive the
vaccine are the military, homosexual men, injection-drug users, day-care workers,
health-care workers, sewage-treatment workers, and food handlers. However, this
strategy of designating selected groups to receive vaccinations has not proven
effective in administering the hepatitis B vaccine. Administering the hepatitis B
vaccine to only high-risk groups has not resulted in any significant reduction in the
frequency of hepatitis B infections.
Once again, pregnant women have not been designated to receive the vaccine.
Why not develop a strategy to vaccinate all those who do not have antibodies against
hepatitis A? Included in this strategy should be adolescents, a group proven to be
extremely sexually active. Screening could be accomplished at STD clinics, family-
planning clinics, and Planned Parenthood clinics at the time of preconceptual
counseling and at the first prenatal visit. The same strategy would apply to the
varicella vaccine soon to be released. No doubt, vaccines developed for frequently
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occurring diseases that have no specific treatment should be administered to the
population that lacks antibodies to that specific agent. The wide distribution of a
vaccine is the only way to eradicate a specific disease, for example, smallpox.
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